Although immune checkpoint inhibition has been shown to effectively activate antitumor
immunity in various tumor types, only a small subset of patients can benefit from PD-1/PD-L1 …

BACKGROUND The authors studied the efficacy of neoadjuvant chemotherapy, consisting
of a taxane, cisplatin, and 5‐fluorouracil (5‐FU) (the TPF regimen) followed by concurrent …

PD-1/PD-L1 blockade has achieved substantial clinical results in cancer treatment. However,
the expression of other immune checkpoints leads to resistance and hinders the efficacy of …

Purpose To evaluate the safety and efficacy of cetuximab plus intensity-modulated radiotherapy
(IMRT) with or without chemotherapy for locoregionally advanced nasopharyngeal …

Nasopharyngeal carcinoma (NPC) is one of the most common malignant tumors with poor
prognosis and recurrence in South China. The hard eradication of NPC in clinic is …

Cancer immunotherapy has emerged as a promising approach in cancer treatment and is
considered a major advancement after surgical interventions, radiotherapy, chemotherapy, …

Objectives: To evaluate long-term outcomes and late toxicities of nasopharyngeal carcinoma
(NPC) patients with T1-2N0-3M0 stage in intensity-modulated radiotherapy (IMRT) era. …

The aim of this study was to investigate the association between the susceptibility of severe
oral mucositis (OM) in Chinese nasopharyngeal carcinoma (NPC) patients treated with …

Developing new therapeutic agents for cancer immunotherapy is highly demanding due to
the low response ratio of PD-1/PD-L1 blockade in cancer patients. Here, we discovered that …

Peptide immune checkpoint inhibitors in cancer immunotherapy have attracted great attention
recently, but oral delivery of these peptides remains a huge challenge due to the harsh …